Navigation Links
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Date:5/31/2008

athy has not been studied in mantle cell lymphoma. Acute development or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, lung infiltration and Acute Respiratory Distress Syndrome in patients receiving VELCADE. Some of these events have been fatal. A higher proportion of these events have been reported in Japan. There have been rare reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Rare cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.

Integrated Safety Data: Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m2/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with multiple myeloma (N=1008) and mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma. In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise, and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuro
'/>"/>

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
3. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
4. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 30, 2014 Passport Health, one of the ... has launched FluFree.com, a website designed to promote, educate ... For 20 years, Passport Health has provided its clients ... launch of FluFree.com is designed to address the growing ... of people who actually chose to get vaccinated. ...
(Date:9/30/2014)... 2014   Acutus Medical, Inc. (ACM), ... 3D Cardiac Chamber Imaging and Dipole Density Mapping system ... sustain complex cardiac arrhythmias, including atrial fibrillation, announced it ... its imaging/mapping system as well as bring to market ... Medical to complete work on the AcQMap TM ...
(Date:9/30/2014)... , Sept. 30, 2014 Headquartered in ... is a diversified company comprised of several specialized partners ... technology and the proven expertise of its team of ... wellness. WholeHealth Products, line of more than 10 professional ... and its more than 8 retail consumer tests is ...
Breaking Medicine Technology:Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 2Passport Health Launches FluFree.com - Aims To Improve Flu Vaccination Rates and Fulfill Growing Public Health Priority 3Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 2Acutus Medical, Inc. Completes Additional $26.2M Series B Financing to Fund Portfolio Expansion 3WholeHealth Products Announces The Discovery Of The "Autism And Fragile X" Microwell And Rapid Diagnostic Test 2
... July 19 Nycomed US Inc. today announced the appointment ... assumes immediate responsibility for Nycomed US Inc., including manufacturing in Melville ... the three marketing and sales divisions Fougera, PharmaDerm and Savage Laboratories. ... Steve Andrzejewski ...
... NEW YORK , July 19 Reportlinker.com announces that a new market research ... , Global Pharma-biotech Alliance ... http://www.reportlinker.com/p0234517/Global-Pharma-biotech-Alliance-Analysis.html , ... This IBD provides an overview of the pharma-biotech alliance deals struck from 2008 to present. ...
Cached Medicine Technology:Steve Andrzejewski Joins Nycomed US Inc. 2Reportlinker Adds Global Pharma-biotech Alliance Analysis 2
(Date:9/30/2014)... has been awarded a three-year $1.7 million grant ... develop new imaging technologies and data analysis techniques ... networks of neurons in the brain interact to ... identify the precise interactions between millions of nerve ... and alterations in these interactions that may be ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 The ... option to help diabetics curb their sweet tooth, but ... Nature this September, suggests that zero-calorie sweeteners may ... 2 diabetes. , The Weizmann Institute of Science ... fed artificial sweeteners to mice, the mice developed glucose ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
(Date:9/30/2014)... Sept. 30, 2014 (HealthDay News) -- Medicare should cover ... high risk for the disease, a coalition of more ... coalition, which includes the Lung Cancer Alliance, the Society ... American Cancer Society and the American Society of Clinical ... to the U.S. Centers for Medicare & Medicaid Services ...
(Date:9/30/2014)... Chicago, IL (PRWEB) September 30, 2014 ... meet at the National Association of Health Advocacy Consultants ... of Healthcare Advocacyā€¯ (#NAHAC14) to be held October 30th ... Making its debut at NAHAC14: Standards and Best Practices ... advocacy grows into a profession, advocates have needed a ...
Breaking Medicine News(10 mins):Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2Health News:Regenerative Medicine Solutions Expanding 2Health News:Groups Call for Medicare Coverage of Lung Cancer Screening 2
... 2012 - VIB researcher Diether Lambrechts, associated with KU ... which patients will benefit more from treatment with bevacizumab ... step towards personalized medicine and patient-tailored use of this ... Leuven) said "in two large clinical studies with patients ...
... symptoms of heart disease already have heart damage, according to ... Heart Failure Congress 2012 , 19-22 May, in Belgrade, Serbia. ... Failure Association of the European Society of Cardiology., ... research has shown that obese adults have structural and functional ...
... Reinberg HealthDay Reporter , FRIDAY, May 18 (HealthDay News) ... Americans born between 1945 and 1965 -- the baby boom generation ... deadly disease occur in this age group, and most were infected ... the agency said. "CDC views this as an unrecognized health ...
... combination of three drugs used worldwide as the standard of ... of death or hospitalization, and should not be used together ... the surprising results of a rigorous independent study. The ... New England Journal of Medicine to coincide with a ...
... For more than three decades, researchers have warned of ... tobacco smoke (ETS), especially among children whose parents smoke. ... University of Arizona reports that those health risks persist ... individuals end up becoming smokers later in life. ...
... , SATURDAY, May 19 (HealthDay News) -- More than ... more than half of those victims are younger than age ... (May 20 to 26), the American Academy of Pediatrics is ... Postal Service to educate people about dog safety. They ...
Cached Medicine News:Health News:Biomarker predicts response to cancer treatment 2Health News:Obese adolescents have heart damage 2Health News:Test Baby Boomers for Hepatitis C, Says CDC 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 2Health News:First, do no harm: Study finds danger in standard treatment for a serious lung disease 3Health News:Study says children exposed to tobacco smoke face long-term respiratory problems 2Health News:Study says children exposed to tobacco smoke face long-term respiratory problems 3Health News:Keeping Your Family Safe From Dog Bites 2
Research® Series 2100 Adjustable-volume Pipette, 0.5-10 µl, single-channel with adjustable-volume setting...
... Seven digital models cover the range from ... liquid fluently. Volume lock design prevents inadvertent ... the horizontal grip. Whole pipette is autoclavable ... ejector is all polypropylene. Suitable for one-handed ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: